liraglutide
Victoza (liraglutide) is a once-daily GLP-1 receptor agonist from Novo Nordisk for type 2 diabetes. A fatty acid tail keeps it in the blood for about a day, boosting meal-time insulin, calming glucagon and slowing stomach emptying to lower blood sugar.
This page is based on FDA prescribing information and the EMA medicine record for liraglutide, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
After meals, the gut normally sends a GLP-1 courier to prepare the pancreas for incoming sugar. Liraglutide is a long-shift courier: a fatty acid tail lets it hitch a ride on blood albumin and keep delivering the message for a whole day, so insulin arrives on time and the liver stops overproducing sugar.
In simple terms
Liraglutide copies the action of GLP-1, a hormone released after eating. It stimulates insulin release when blood sugar is high, reduces glucagon, which raises sugar, and slows how quickly food leaves the stomach. These effects together lower blood sugar in type 2 diabetes. It is injected under the skin once daily.
In depth
Liraglutide is a GLP-1 analogue acylated with a palmitic acid side chain at lysine 26, enabling reversible albumin binding that slows renal clearance and extends half-life to 11-15 hours. It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release and delay gastric emptying. The same molecule at a higher dose underlies the obesity formulation, reflecting appetite-suppressing central effects of GLP-1 agonism.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How liraglutide's palmitic-acid tail lets it lower blood sugar for a whole day
- Liraglutide is a GLP-1 analogue acylated with a palmitic acid side chain at lysine 26, enabling reversible albumin binding that slows renal clearance and extends half-life to 11-15 hours.
- It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release and delay gastric emptying.
- It is injected under the skin once daily.
- The same molecule at a higher dose underlies the obesity formulation, reflecting appetite-suppressing central effects of GLP-1 agonism.
Target: GLP-1 receptor
The receptor for the incretin hormone GLP-1; activating it makes the pancreas release insulin when glucose rises, suppresses glucagon and slows gastric emptying.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- As an adjunct to diet and exercise, to improve glycemic control in adults and children 10 years of age and older with type 2 diabetes mellitus
Approved uses in European Union
EMA- In adults, adolescents and children aged 10 years and above, for insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is inappropriate, or in addition to other medicinal products for the treatment of diabetes
Official sources
The statements on this page trace back to these records.
- Victoza (liraglutide) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: liraglutide prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: liraglutide
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.